There has been recent progress in the field of treatmetn for patients with HIV/HCV co-infection.
View on-demand web symposium on the treatment of patients with HIV/HCV co-infection.
This program is available in English, French, and Spanish.
This CME dinner series has been designed to focus on recent advances in chronic hepatitis C (CHC) treatment, especially newly approved therapies. A national thought leader will lead participants through an overview of the updated CHC treatment paradigms and present detailed clinical trial data on newer therapies and strategies that are expected to shape treatment paradigms in the near future.
Douglas T. Dieterich, MD
Professor of Medicine,
Director of Outpatient Hepatology, Division of Liver Diseases
Director of CME, Department of Medicine,
Mount Sinai School of Medicine
New York, New York
In recent years, significant progress has been made regarding the therapeutic options for chronic hepatitis C (CHC). This progress has the potential to significantly improve treatment success and tolerability rates; however, in order for that to occur, health care providers (HCPs) must be aware of the full range of treatment options currently available or in development. HCPs without this knowledge and ability have professional practice gaps that are likely to adversely affect CHC treatment outcomes.
This CME dinner series and related online program have been designed to address these practice gaps by updating clinicians on recent advances in CHC treatment, especially newer therapies. National thought leaders will lead participants through an overview of the current CHC treatment paradigms and present detailed clinical trial data on newly approved therapies and strategies and discuss products in development that are expected to shape treatment decisions in the near future. It is the goal of this program to address treatment gaps and provide clinicians with the tools needed to adjust their behavior so that they can provide optimal care to patients with CHC, thereby reducing morbidity and mortality associated with CHC.
National thought leaders lead this program using case-based panel discussions to drive home key messages regarding HBV diagnosis, monitoring and treatment while discussing barriers unique to different ethnic communities. Presenters will discuss transmission of HBV in various populations; symptoms of HBV infection; long-term risk and consequences of untreated HBV infection; major treatment guidelines for the diagnosis and management of patients with HBV infection; and the treatment of special populations of patients with HBV infection so that more patients can be screened or tested for HBV and receive the full benefit of available treatments for CHB, leading to decreased morbidity and mortality.
Paul Kwo, MD Associate Professor of Medicine, Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana | Mark Sulkowski, MD Associate Professor of Medicine, Medical Director, Viral Hepatitis Center Johns Hopkins University School of Medicine Baltimore, Maryland |
Tram Tran, MD Medical Director, Liver Transplantation Cedars-Sinai Medical Center Associate Professor, University of California, Los Angeles Los Angeles, California |
CME programs from DDW.
Watch on-demand CME symposium in English, Spanish, and French.
Also includes CME newsletter.
Watch videos from important topics delivered by experts in HCV management at the recent CONO Conference, including:
- HCV epidemiology
- The use of HCV protease inhbitors
- New drugs in development
- The treatment of special populations
Douglas T. Dieterich, MD Professor of Medicine Director of Outpatient Hepatology, Division of Liver Diseases Director of CME, Department of Medicine, Mount Sinai School of Medicine New York, New York |
Paul J. Pockros, MD Head, Division of Gastroenterology/Hepatology Director, SC Liver Research Consortium The Scripps Clinic La Jolla, California |
Mark Sulkowski, MD Associate Professor of Medicine and Medical Director, Viral Hepatitis Center, Johns Hopkins University School of Medicine Baltimore, Maryland |
This CME activity will feature four HCV experts reviewing and discussing the most important studies presented on chronic hepatitis C at EASL. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at EASL and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This program will enable all participating clinicians and health care providers caring for HCV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine,
Director of Outpatient Hepatology,
Division of Liver Diseases,
Mount Sinai School of Medicine
New York, New York
Paul Y. Kwo, MD
Associate Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Jürgen Rockstroh, MD
Professor
University of Bonn
Bonn, Germany
Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California
This 1.5 hour Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at the 62nd AASLD. The symposium will feature 4 well-known and recognized thought leaders in the HCV field. This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection.
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center,
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California
K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
There has been significant recent progress in the management of patients with chronic hepatitis C (CHC), and cure rates continue to rise. However, before the millions of Americans with CHC can receive the full benefits of treatment, they must be diagnosed and appropriately treated. Physicians therefore need to learn how to identify those with CHC and provide optimal treatment for each patient, including an understanding of HCV genotypes, treatment schedules, drug-drug interactions, and the management of adverse effects, such as rash and anemia.
This live, two-hour long CME activity places an emphasis on updating treatment algorithms with new treatment options and reviewing new agents in development that impact treatment decisions made today.
Mark Sulkowski, MD | Paul Y. Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana |
Over three million people in the United States have chronic HCV infection (CHC). CHC is the leading cause of cirrhosis and a common cause of hepatocellular carcinoma and liver transplantation. Fortunately, treatments exist that can often reduce the morbidity and mortality of CHC and the response rate to antiviral therapy is predicted to improve with the introduction of newer treatment options, including protease inhibitors, entry inhibitors and polymerase inhibitors. To improve patient outcomes, clinicians need to be aware of all treatment options and how to integrate them into current treatment algorithms. They also need to address problems with adherence to reduce the risk of resistance.
This online activity has been designed to focus on recent advances in CHC treatment, especially newer therapies. Three national thought leaders will lead viewers participants through an overview of the current CHC treatment paradigms and present detailed clinical trial data on newer therapies and strategies that are expected to shape treatment paradigms in the near future.
Bruce R. Bacon, MD |
Paul Y. Kwo, MD |
Mark Sulkowski, MD |
This 1.5-hour Internet symposium reviews and discusses the key studies on chronic hepatitis C management and treatment presented at EASL. The symposium will feature four well-known and recognized thought leaders in the HCV field, with three serving as presenting faculty/discussants and one as program moderator. This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection.
This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.
In addition to videos (available in French, English, and Spanish), the program offers poster reviews, slide presentations, and a CME newsletter.
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California
K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
This Internet symposium will review and discuss the key studies on chronic hepatitis C management and treatment presented at EASL. The symposium will feature four well-known and recognized thought leaders in the HCV field, with three serving as presenting faculty/discussants and one as program moderator.
This activity has been designed to meet the educational needs of physicians involved in the care of patients with chronic hepatitis C infection. This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.
Mark Sulkowski, MD
Associate Professor of Medicine and Medical Director,
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Nezam H. Afdhal, MD
Associate Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology, Director of Liver Center,
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Fred Poordad, MD
Chief, Hepatology
Cedars-Sinai Medical Center
Associate Professor of Medicine,
David Geffen School of Medicine at UCLA
Los Angeles, California
K. Rajender Reddy, MD
Professor of Medicine,
Director of Hepatology,
Medical Director of Liver Transplantation
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania